Exact Mass: 383.0022

Exact Mass Matches: 383.0022

Found 77 metabolites which its exact mass value is equals to given mass value 383.0022, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ceftizoxime

(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C13H13N5O5S2 (383.0358)


A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. [PubChem] J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

Carfentrazone

Carfentrazone-ethyl metabolite

C13H10Cl2F3N3O3 (383.0051)


   

IMD 0354

N-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide

C15H8ClF6NO2 (383.0148)


   

clofarabind-5'-monophosphate

{[(2S,3S,4S,5S)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methoxy}phosphonic acid

C10H12ClFN5O6P (383.0198)


clofarabind-5-monophosphate is a metabolite of clofarabine. Clofarabine is a purine nucleoside antimetabolite marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. It is not known if it extends life expectancy. (Wikipedia)

   

Althiazide

6-Chloro-1,1-dioxo-3-(prop-2-enylsulphanylmethyl)-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulphonamide

C11H14ClN3O4S3 (382.9835)


C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic

   

Cystine-glutamate

4,9,14-triamino-1,2,11,12-tetraoxa-6,7-dithiacycloheptadecane-3,10,13,17-tetrone

C11H17N3O8S2 (383.0457)


   

N-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide

N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide

C15H8ClF6NO2 (383.0148)


   

3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile

3-{[(1S)-2,2-difluoro-1-hydroxy-7-(methylsulphonyl)-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile

C17H12F3NO4S (383.0439)


   

Belzutifan

3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methanesulphonyl-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile

C17H12F3NO4S (383.0439)


   
   
   
   
   
   
   
   
   

(+)-discorhabdin E|Discorhabdin E

(+)-discorhabdin E|Discorhabdin E

C18H14BrN3O2 (383.0269)


   

iodo-ammosamide B

iodo-ammosamide B

C12H10IN5O2 (382.9879)


   

C(=O)(O)CS(=O)C1=C(N2C(C(C2C1)C(C)OS(=O)(=O)O)=O)C(=O)O

C(=O)(O)CS(=O)C1=C(N2C(C(C2C1)C(C)OS(=O)(=O)O)=O)C(=O)O

C11H13NO10S2 (382.9981)


   

althiazide

althiazide

C11H14ClN3O4S3 (382.9835)


C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic

   
   
   
   

1-bromo-4-(cyclohexylamino)anthracene-9,10-dione

1-bromo-4-(cyclohexylamino)anthracene-9,10-dione

C20H18BrNO2 (383.0521)


   
   

ML216

1-(4-Fluoro-3-(trifluoromethyl)phenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea

C15H9F4N5OS (383.0464)


   
   

6-(2,6-Dichlorophenyl)-8-methyl-2-methylsulfonyl-8H-pyrido[2,3-d]pyrimidin-7-one

6-(2,6-Dichlorophenyl)-8-methyl-2-methylsulfonyl-8H-pyrido[2,3-d]pyrimidin-7-one

C15H11Cl2N3O3S (382.9898)


   

4-bromo-N,N-bis(4-Methoxyphenyl)aniline

4-bromo-N,N-bis(4-Methoxyphenyl)aniline

C20H18BrNO2 (383.0521)


   

(2,3-Dihydro-2-thioxo-3-benzoxazolyl)phosphonic acid diphenyl ester

(2,3-Dihydro-2-thioxo-3-benzoxazolyl)phosphonic acid diphenyl ester

C19H14NO4PS (383.0381)


   

4-(4-BROMOPHENYL)-2-(4-(TRIFLUOROMETHYL)PHENYL)THIAZOLE

4-(4-BROMOPHENYL)-2-(4-(TRIFLUOROMETHYL)PHENYL)THIAZOLE

C16H9BrF3NS (382.9591)


   

d-glucosamine-2,3-disulfate, disodium salt

d-glucosamine-2,3-disulfate, disodium salt

C6H11NNa2O11S2 (382.9569)


   

potassium [[N,N-ethylenebis[N-(carboxymethyl)glycinato]](4-)-N,N,O,O,ON,ON]ferrate(1-)

potassium [[N,N-ethylenebis[N-(carboxymethyl)glycinato]](4-)-N,N,O,O,ON,ON]ferrate(1-)

C10H12FeKN2O8 (382.958)


   

5-iodo-2-o-methylcytidine

5-iodo-2-o-methylcytidine

C10H14IN3O5 (382.9978)


   

azane,trichloroiridium

azane,trichloroiridium

Cl3H15IrN5 (383.0022)


   

3-BENZYLOXY-4-IODO-5-NITRO-BENZALDEHYDE

3-BENZYLOXY-4-IODO-5-NITRO-BENZALDEHYDE

C14H10INO4 (382.9655)


   

Echothiophate Iodide

Echothiophate Iodide

C9H23INO3PS (383.0181)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors

   

2-([(4-bromophenyl)sulfonyl]amino)-3-phenylpropanoic acid

2-([(4-bromophenyl)sulfonyl]amino)-3-phenylpropanoic acid

C15H14BrNO4S (382.9827)


   

5-Chloro-3-ethyl-2-methylbenzothiazolium p-toluenesulfonate

5-Chloro-3-ethyl-2-methylbenzothiazolium p-toluenesulfonate

C17H18ClNO3S2 (383.0417)


   

2-Benzyl-5-chloro-6-iodoisoindolin-1-one

2-Benzyl-5-chloro-6-iodoisoindolin-1-one

C15H11ClINO (382.9574)


   

(2-amino-4,5-dihydroxy-1-oxo-6-sulfooxyhexan-3-yl) hydrogen sulfate,sodium

(2-amino-4,5-dihydroxy-1-oxo-6-sulfooxyhexan-3-yl) hydrogen sulfate,sodium

C6H11NNa2O11S2 (382.9569)


   

4-(4-Bromo-1H-pyrazol-1-yl)-N-cyclohexylbenzenesulfonamide

4-(4-Bromo-1H-pyrazol-1-yl)-N-cyclohexylbenzenesulfonamide

C15H18BrN3O2S (383.0303)


   

1-acetamido-8-hydroxy-3,6-naphthalenedisulfonic acid monosodium salt

1-acetamido-8-hydroxy-3,6-naphthalenedisulfonic acid monosodium salt

C12H10NNaO8S2 (382.9746)


   

6-Bromo-13-Thia-2,4,8,12,19-Pentaazatricyclo[12.3.1.1~3,7~]nonadeca-1(18),3(19),4,6,14,16-Hexaene 13,13-Dioxide

6-Bromo-13-Thia-2,4,8,12,19-Pentaazatricyclo[12.3.1.1~3,7~]nonadeca-1(18),3(19),4,6,14,16-Hexaene 13,13-Dioxide

C13H14BrN5O2S (383.0052)


   

Belzutifan

Belzutifan

C17H12F3NO4S (383.0439)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D000970 - Antineoplastic Agents Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC)[1].

   

Perfluoro-N-ethylpiperidine

Perfluoro-N-ethylpiperidine

C7F15N (382.9791)


   

2,5-dichloro-N-(1,5,6-trimethyl-4-benzimidazolyl)benzenesulfonamide

2,5-dichloro-N-(1,5,6-trimethyl-4-benzimidazolyl)benzenesulfonamide

C16H15Cl2N3O2S (383.0262)


   

1-Bromo-8,8-dimethyl-8,9-dihydro-5-morpholino-6h-isothiazolo[5,4-b]pyrano[4,3-d]pyridine

1-Bromo-8,8-dimethyl-8,9-dihydro-5-morpholino-6h-isothiazolo[5,4-b]pyrano[4,3-d]pyridine

C15H18BrN3O2S (383.0303)


   

N-[3,4-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-chlorobenzamide

N-[3,4-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-chlorobenzamide

C15H8ClF6NO2 (383.0148)


   

2-Bromo-8-hydroxyspiro[6,10,15-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2(7),4,8,10,12(16)-hexaene-3,4-cyclohex-2-ene]-1-one

2-Bromo-8-hydroxyspiro[6,10,15-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2(7),4,8,10,12(16)-hexaene-3,4-cyclohex-2-ene]-1-one

C18H14BrN3O2 (383.0269)


   

3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile

3-{[(1S)-2,2-difluoro-1-hydroxy-7-(methylsulphonyl)-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile

C17H12F3NO4S (383.0439)


   

[(1R)-1-[(7S)-2-amino-7-methyl-4-oxo-7,8-dihydro-3H-pteridin-6-yl]ethyl] phosphono hydrogen phosphate

[(1R)-1-[(7S)-2-amino-7-methyl-4-oxo-7,8-dihydro-3H-pteridin-6-yl]ethyl] phosphono hydrogen phosphate

C9H15N5O8P2 (383.0396)


   

4,9,14-triamino-1,2,11,12-tetraoxa-6,7-dithiacycloheptadecane-3,10,13,17-tetrone

4,9,14-triamino-1,2,11,12-tetraoxa-6,7-dithiacycloheptadecane-3,10,13,17-tetrone

C11H17N3O8S2 (383.0457)


   

Ethylmercurithiosalicylate

Ethylmercurithiosalicylate

C9H9HgO2S- (383.003)


   

6-[[(4-Chlorophenyl)thio]methyl]-2-phenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione

6-[[(4-Chlorophenyl)thio]methyl]-2-phenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione

C19H14ClN3O2S (383.0495)


   

5-bromo-N-[2-(3-pyridinyl)-1,3-benzoxazol-5-yl]-2-furancarboxamide

5-bromo-N-[2-(3-pyridinyl)-1,3-benzoxazol-5-yl]-2-furancarboxamide

C17H10BrN3O3 (382.9905)


   

3,7-dichloro-N-[3-(1-imidazolyl)propyl]-6-methoxy-1-benzothiophene-2-carboxamide

3,7-dichloro-N-[3-(1-imidazolyl)propyl]-6-methoxy-1-benzothiophene-2-carboxamide

C16H15Cl2N3O2S (383.0262)


   

3-(2-chlorophenyl)-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-methyl-4-isoxazolecarboxamide

3-(2-chlorophenyl)-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-methyl-4-isoxazolecarboxamide

C19H14ClN3O2S (383.0495)


   

N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide

N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide

C16H12F3N3OS2 (383.0374)


   

5-Bromo-2-furancarboxylic acid [2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester

5-Bromo-2-furancarboxylic acid [2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester

C16H18BrNO5 (383.0368)


   

2-(4-chlorophenoxy)-N-(2-thiophen-2-yl-3-imidazo[1,2-a]pyridinyl)acetamide

2-(4-chlorophenoxy)-N-(2-thiophen-2-yl-3-imidazo[1,2-a]pyridinyl)acetamide

C19H14ClN3O2S (383.0495)


   

5-Bromo-4-chloro-2-(4-methoxybenzamido)benzoic acid

5-Bromo-4-chloro-2-(4-methoxybenzamido)benzoic acid

C15H11BrClNO4 (382.956)


   

2-(2-chloro-4-fluorophenoxy)-N-[5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl]acetamide

2-(2-chloro-4-fluorophenoxy)-N-[5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl]acetamide

C16H9ClF3N3O3 (383.0285)


   

(2S)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid

(2S)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid

C13H10Cl2F3N3O3 (383.0051)


   
   

(2R)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid

(2R)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid

C13H10Cl2F3N3O3 (383.0051)


   

sodium (2R)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate

sodium (2R)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate

C15H10ClF3NNaO4 (383.0148)


   

sodium (2S)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate

sodium (2S)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate

C15H10ClF3NNaO4 (383.0148)


   

ceftizoxime

ceftizoxime

C13H13N5O5S2 (383.0358)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

clofarabind-5-monophosphate

clofarabind-5-monophosphate

C10H12ClFN5O6P (383.0198)


   

Nelonemdaz

Nelonemdaz

C15H8F7NO3 (383.0392)


Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death[1][2].

   

PT-2385

PT-2385

C17H12F3NO4S (383.0439)


PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].

   

(1r)-3-bromo-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),4',9'(16'),11'-hexaene-4,8'-dione

(1r)-3-bromo-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),4',9'(16'),11'-hexaene-4,8'-dione

C18H14BrN3O2 (383.0269)


   

(2r)-4-(4-bromo-2,6-dichlorophenoxy)-2-(trimethylammonio)butanoate

(2r)-4-(4-bromo-2,6-dichlorophenoxy)-2-(trimethylammonio)butanoate

C13H16BrCl2NO3 (382.9691)


   

(1s)-5-bromo-8'-hydroxy-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),5,8',10',12'(16')-heptaen-4-one

(1s)-5-bromo-8'-hydroxy-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),5,8',10',12'(16')-heptaen-4-one

C18H14BrN3O2 (383.0269)


   

3-bromo-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),4',9'(16'),11'-hexaene-4,8'-dione

3-bromo-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),4',9'(16'),11'-hexaene-4,8'-dione

C18H14BrN3O2 (383.0269)